Oliver Schon Email and Phone Number
Oliver Schon work email
- Valid
- Valid
Oliver Schon personal email
As part of the Executive Senior Management at BiVictriX Therapeutics, I deliver on strategic and operational goals against publicly announced objectives. I oversee the entireBVX research activity (internal & external) to bring the best lead molecule to pre-clinical development. I deliver on ambitious goals by creating a collaborative culture, capability and conviction.Strong line leader recognised for peer and team development through mentoring & coaching across functions. I deliver on objectives through integrity and by holding myself, the team & others accountable for delivering quality results – every time.
-
Biotech Consultant - Cso And FounderBiomind Consultants LtdCambridge, Gb
-
Vp, Head Of Research & Development @ BivictrixBivictrix Therapeutics Plc Apr 2023 - PresentMacclesfield, Cheshire, Gb
-
Vp, Product Development & CmcBivictrix Therapeutics Plc Sep 2021 - Apr 2023Macclesfield, Cheshire, GbI joined a fledging SME tasked to define and develop the USPs for this Bispecific ADC(antibody drug conjugate) venture with ambitious timelines to clinical development. Asa public company (AIM: BVX.L), I update the Board of Directors (BoD) on progressand provide strategy & mitigation plans in support of company objectives. The roleremit is broad spanning team & technical capability set-up, developability assessmentof leads against Target&Product Profile, CDMO/CRO engagement & management,biological target & lead compound discovery, new technology development as well asIP & publications. #bench-to-bedside
-
Freelance Biotech ConsultantFreelance Jan 2022 - PresentI advise & consult on early biotech projects, therapeutic pipeline projects and platforms as well as developability assessments of lead panels up to Candidate Selection and CLD. Deep expertise in applying Quality by Design, defining Target Product Profiles & implementing robust processes for a variety of different therapeutic modalities. Flexible approach to meet your needs.
-
Director - Head, Protein Sciences & Manufacturing Cell Line Development @ AgenusAgenus Nov 2018 - Sep 2021Lexington, Massachusetts, UsI rebuilt a dedicated team of scientists to support ambitious manufacturing CLD projects @ Agenus to RCB. Innovative and disruptive 'Ways of Working' enable on-time delivery of mAb and multi-specific NBE lead candidates in readiness of manufacture. Team efforts are fully aligned to Lead Discovery & Protein Science Departments to maximize on >>Best Science and Speed<<. -
Director, Head Protein Sciences @ AgenusAgenus Mar 2017 - Nov 2018Lexington, Massachusetts, UsI accomplish complex and stretched objectives through a high performing team of dedicated protein biochemists & engineers supporting and driving the entire NBE AGENUS pipeline through to Candidate Selection and INDs. I am modality agnostic in my commitment to fight human disease by strategically employing AGENUS' proprietary therapeutic platforms to select best candidates and outcomes for patients.
-
Scientific Manager, Research Projects - Cell TherapyGsk Oct 2016 - Mar 2017Brentford, Middlesex, GbTouting for external platform and technology opportunities to supplement GSK's Cell&Gene Therapy ambition. Aligning with Therapy Area Units to define and realise the best synergy between external technologies and value to GSK and future patients. -
Scientific Manager, Transgene Discovery - Cell TherapyGsk Feb 2015 - Sep 2016Brentford, Middlesex, GbI project managed GSK's first internal CAR-T (chimeric antigen receptor) C> Platform team establishing internal technical capabilities while simultaneously aligning stakeholder expectations and ways of working across different teams. The project now has been terminated due to strategic considerations, however with processes, protocols and functional assays in place to be used by the next therapeutic CART project @ GSK.
-
External Technology Leader - NbesGsk Aug 2014 - Feb 2016Brentford, Middlesex, GbI was accountable for project management & scientific rigour of a biopharm/sustained release feasibility study (‘monthly dosing interval for clinical AlbudAbTM asset’). I conducted the landscape analysis, due diligence & stakeholder management right from inception of the project. The progression of the collaboration was challenged by the termination of the clinical asset (DEC14), which I communicated in a transparent manner to internal & external partners. Following a stringent Target&Product Profile, the evaluation has achieved every success criteria within budget and on time. I was commended by internal & external stakeholders for my scientific lead and communication.
-
Group Leader, Nbe Profiling & AnalysisGsk Mar 2012 - Dec 2014Brentford, Middlesex, GbCharacterisation of novel NBE formats ('3rd generation') to enable CMC, developability and mechanistic (biological MoA) data package for therapeutic partners and pre-clinical entry. Requires close engagement with various departments from USP/DSP, biology, global safety and IP.
-
Programme Lead 'Albudabs' - NbesGsk Mar 2009 - Mar 2012Brentford, Middlesex, GbI was the program lead of the 'AlbudAb Platform Technology', a serum half-life extending technology for biologics/NBEs as well as NCEs. Numerous AlbudAb-based therapeutics now have entered pre-clinical/clinical development. I also continue to be group leader for the bio-analytics for the targeted BDU, Cambridge, with ever extending analytical capabilities, focussing on in-solution states, forced degradation and structural information.
-
Team Leader 'Biophysical Analysis' - NbesGsk Jan 2007 - Mar 2012Brentford, Middlesex, GbGroup Leader for the quantitative analysis and characterisation of antibody variable domains (dAbs) as single dAbs and final therapeutic drug candidates using DLS, DSC, AUC, MALLS, BIAcore amongst other routine laboratory techniques.Lead candidate selection based on solution properties and bio-informatics.
-
Scientist Bioanalytics R&DDomantis Ltd. Sep 2003 - Dec 2006GbCharacterisation of single domain antibodies (dAbs) as a new entity of fully sized IgG molecules as potential drugs. Basic research and publication-focussed with emphasis on phage selections and dAb expression. -
Research Fellow/Post DocMedical Research Council Sep 2002 - Aug 2003Swindon, GbDomantis sponsored Post doc with Nobel Price Laureate (2018) Sir Gregory Winter on the biophysical characterisation of single-domain antibodies. This work has been continued and expanded into a full time engagement at Domantis.
Oliver Schon Skills
Oliver Schon Education Details
-
University Of CambridgePh.D Course - Biophysics; Cancer Research -
University Of CologneMolecular Biology/Plant Sciences; Biology
-
Norbert Gymnasium KnechtstedenAbitur
Frequently Asked Questions about Oliver Schon
What company does Oliver Schon work for?
Oliver Schon works for Biomind Consultants Ltd
What is Oliver Schon's role at the current company?
Oliver Schon's current role is Biotech Consultant - CSO and Founder.
What is Oliver Schon's email address?
Oliver Schon's email address is o.****@****tab.net
What schools did Oliver Schon attend?
Oliver Schon attended University Of Cambridge, University Of Cologne, Norbert Gymnasium Knechtsteden.
What skills is Oliver Schon known for?
Oliver Schon has skills like Drug Discovery, Antibodies, R&d, Biophysics, Protein Chemistry, Life Sciences, Lifesciences, Clinical Development, Bioinformatics, Drug Development, Biopharmaceuticals, Bioanalysis.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial